Xiamen Amoytop Biotech Performance dei guadagni passati
Il passato criteri di controllo 5/6
Xiamen Amoytop Biotech has been growing earnings at an average annual rate of 45.6%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 27.7% per year. Xiamen Amoytop Biotech's return on equity is 32.7%, and it has net margins of 28.5%.
Informazioni chiave
45.6%
Tasso di crescita degli utili
44.9%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 11.3% |
| Tasso di crescita dei ricavi | 27.7% |
| Rendimento del capitale proprio | 32.7% |
| Margine netto | 28.5% |
| Ultimo aggiornamento sui guadagni | 30 Sep 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) 26% Jump Shows Its Popularity With Investors
Sep 19
Investors Appear Satisfied With Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Prospects As Shares Rocket 26%
Sep 19Is There An Opportunity With Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) 50% Undervaluation?
Jun 12Xiamen Amoytop Biotech (SHSE:688278) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 04Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Share Price Could Signal Some Risk
Mar 25Ripartizione dei ricavi e delle spese
Come Xiamen Amoytop Biotech guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Sep 24 | 2,595 | 741 | 1,271 | 279 |
| 30 Jun 24 | 2,387 | 658 | 1,179 | 265 |
| 31 Mar 24 | 2,226 | 600 | 1,126 | 234 |
| 31 Dec 23 | 2,100 | 555 | 1,058 | 229 |
| 30 Sep 23 | 1,843 | 456 | 951 | 190 |
| 30 Jun 23 | 1,716 | 356 | 921 | 174 |
| 31 Mar 23 | 1,601 | 314 | 867 | 166 |
| 31 Dec 22 | 1,527 | 287 | 840 | 149 |
| 30 Sep 22 | 1,466 | 254 | 852 | 124 |
| 30 Jun 22 | 1,378 | 243 | 832 | 93 |
| 31 Mar 22 | 1,262 | 204 | 772 | 83 |
| 31 Dec 21 | 1,132 | 181 | 698 | 80 |
| 30 Sep 21 | 1,043 | 168 | 629 | 86 |
| 30 Jun 21 | 904 | 142 | 552 | 79 |
| 31 Mar 21 | 822 | 128 | 506 | 76 |
| 31 Dec 20 | 794 | 117 | 503 | 74 |
| 30 Sep 20 | 762 | 98 | 495 | 57 |
| 30 Jun 20 | 771 | 95 | 495 | 57 |
| 31 Mar 20 | 771 | 86 | 505 | 52 |
| 31 Dec 19 | 730 | 64 | 485 | 50 |
| 30 Sep 19 | 665 | 58 | 441 | 50 |
| 31 Dec 18 | 448 | 16 | 319 | 38 |
| 31 Dec 17 | 323 | 5 | 255 | 18 |
| 31 Dec 16 | 280 | 29 | 203 | 9 |
Guadagni di qualità: 688278 has a high level of non-cash earnings.
Margine di profitto in crescita: 688278's current net profit margins (28.5%) are higher than last year (24.7%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: 688278's earnings have grown significantly by 45.6% per year over the past 5 years.
Accelerare la crescita: 688278's earnings growth over the past year (62.6%) exceeds its 5-year average (45.6% per year).
Guadagni vs Settore: 688278 earnings growth over the past year (62.6%) exceeded the Biotechs industry 0.08%.
Rendimento del capitale proprio
ROE elevato: 688278's Return on Equity (32.7%) is considered high.